These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 24620799)

  • 21. Imaging mass spectrometry in drug discovery and development.
    Oppenheimer SR; Wehr AY
    Bioanalysis; 2015; 7(20):2609-10. PubMed ID: 26542100
    [No Abstract]   [Full Text] [Related]  

  • 22. Metabolite identification by mass spectrometry: forty years of evolution.
    Wright P
    Xenobiotica; 2011 Aug; 41(8):670-86. PubMed ID: 21434771
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in Mass Spectrometry Within Drug Discovery.
    Wingfield J; Wilson ID
    J Biomol Screen; 2016 Feb; 21(2):109-10. PubMed ID: 26773070
    [No Abstract]   [Full Text] [Related]  

  • 24. Current applications of liquid chromatography/mass spectrometry in pharmaceutical discovery after a decade of innovation.
    Ackermann BL; Berna MJ; Eckstein JA; Ott LW; Chaudhary AK
    Annu Rev Anal Chem (Palo Alto Calif); 2008; 1():357-96. PubMed ID: 20636083
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Now's the time to find biomarkers on purpose.
    Auman JT; McLeod HL
    Ann Oncol; 2010 Feb; 21(2):193-194. PubMed ID: 20047974
    [No Abstract]   [Full Text] [Related]  

  • 26. Proof of concept: a PhRMA position paper with recommendations for best practice.
    Cartwright ME; Cohen S; Fleishaker JC; Madani S; McLeod JF; Musser B; Williams SA
    Clin Pharmacol Ther; 2010 Mar; 87(3):278-85. PubMed ID: 20130568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How pharmacogenomics (PG) are changing practice: implications for prescribers, their patients, and the healthcare system (PG series part I).
    Preskorn SH; Hatt CR
    J Psychiatr Pract; 2013 Mar; 19(2):142-9. PubMed ID: 23507814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analytical validation of accelerator mass spectrometry for pharmaceutical development.
    Keck BD; Ognibene T; Vogel JS
    Bioanalysis; 2010 Mar; 2(3):469-85. PubMed ID: 21083256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of biomarkers in human pharmacology (Phase I) studies.
    Cohen AF; Burggraaf J; van Gerven JM; Moerland M; Groeneveld GJ
    Annu Rev Pharmacol Toxicol; 2015; 55():55-74. PubMed ID: 25292425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The quest for biomarkers in tuberculosis.
    Parida SK; Kaufmann SH
    Drug Discov Today; 2010 Feb; 15(3-4):148-57. PubMed ID: 19854295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From biomarker strategies to biomarker activities and back.
    van Gool AJ; Henry B; Sprengers ED
    Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-resolution chromatography/time-of-flight MSE with in silico data mining is an information-rich approach to reactive metabolite screening.
    Barbara JE; Castro-Perez JM
    Rapid Commun Mass Spectrom; 2011 Oct; 25(20):3029-40. PubMed ID: 21953957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conference report: summary of the 2010 Applied Pharmaceutical Analysis Conference.
    Unger SE
    Bioanalysis; 2011 Jan; 3(1):11-5. PubMed ID: 21175361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metabolomics and its potential in drug development.
    Beyoğlu D; Idle JR
    Biochem Pharmacol; 2013 Jan; 85(1):12-20. PubMed ID: 22935449
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-throughput liquid chromatography/mass spectrometry method for the quantitation of small molecules using accurate mass technologies in supporting discovery drug screening.
    Ding X; Ghobarah H; Zhang X; Jaochico A; Liu X; Deshmukh G; Liederer BM; Hop CE; Dean B
    Rapid Commun Mass Spectrom; 2013 Feb; 27(3):401-8. PubMed ID: 23280971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Special section: 23rd International Symposium on Pharmaceutical and Biomedical Analysis (PBA 2011), 9-12 october 2011, João Pessoa, PB, Brazil.Preface.
    Cass QB
    J Pharm Biomed Anal; 2013 Jan; 73():1-2. PubMed ID: 22785375
    [No Abstract]   [Full Text] [Related]  

  • 37. Tiered approach to metabolite quantification: regional practices reviewed by Japan Bioanalysis Forum discussion group.
    Niwa M; Uchimura T; Koseki N; Satsukawa M; Hashimoto Y; Mayumi T; Yasuda Y; Yokoi H
    Bioanalysis; 2015; 7(8):935-8. PubMed ID: 25966006
    [No Abstract]   [Full Text] [Related]  

  • 38. Weak affinity chromatography for evaluation of stereoisomers in early drug discovery.
    Duong-Thi MD; Bergström M; Fex T; Svensson S; Ohlson S; Isaksson R
    J Biomol Screen; 2013 Jul; 18(6):748-55. PubMed ID: 23479356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human pluripotent stem cells in drug discovery and predictive toxicology.
    Laustriat D; Gide J; Peschanski M
    Biochem Soc Trans; 2010 Aug; 38(4):1051-7. PubMed ID: 20659002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mass spectrometry for small molecule pharmaceutical product development: a review.
    Gillespie TA; Winger BE
    Mass Spectrom Rev; 2011; 30(3):479-90. PubMed ID: 21500245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.